RT Journal Article
T1 Spanish Cell Therapy Network (TerCel): 15 years of successful collaborative translational research.
A1 Sánchez-Guijo, Fermín
A1 García-Olmo, Damián
A1 Prósper, Felipe
A1 Martínez, Salvador
A1 Zapata, Agustín
A1 Fernández-Avilés, Francisco
A1 Toledo-Aral, Juan José
A1 Torres, Miguel
A1 Fariñas, Isabel
A1 Badimón, Lina
A1 Labandeira-García, José Luis
A1 García-Sancho, Javier
A1 Moraleda, José M
A1 TerCel, 
K1 cell therapy
K1 regenerative medicine
K1 research network
K1 stem cells
K1 translational medicine
AB In the current article we summarize the 15-year experience of the Spanish Cell Therapy Network (TerCel), a successful collaborative public initiative funded by the Spanish government for the support of nationwide translational research in this important area. Thirty-two research groups organized in three programs devoted to cardiovascular, neurodegenerative and immune-inflammatory diseases, respectively, currently form the network. Each program has three working packages focused on basic science, pre-clinical studies and clinical application. TerCel has contributed during this period to boost the translational research in cell therapy in Spain, setting up a network of Good Manufacturing Practice-certified cell manufacturing facilities- and increasing the number of translational research projects, publications, patents and clinical trials of the participating groups, especially those in collaboration. TerCel pays particular attention to the public-private collaboration, which, for instance, has led to the development of the first allogeneic cell therapy product approved by the European Medicines Agency, Darvadstrocel. The current collaborative work is focused on the development of multicenter phase 2 and 3 trials that could translate these therapies to clinical practice for the benefit of patients.
YR 2019
FD 2019-12-19
LK http://hdl.handle.net/10668/14868
UL http://hdl.handle.net/10668/14868
LA en
DS RISalud
RD Apr 17, 2025